Road to profitability is in sight as management continues to take the right steps.

The ASX's biggest healthcare name saw its shares fall after reporting first-half results.

Solid device sales with shares moderately undervalued.

We raise our fair value on this high-flyer.

Shares drop 17% after guidance is revised but we still see value.

The shares are trading at a 47% premium to our fair value.

Fair value uneffected by suspended early-stage clinical trials.

Good news as a proposed merger is approved but investors may be too optimistic. 

Solid global sales and margin expansion are highlights from latest quarter.

Proceeds from the sale don’t make up for lost earnings.